Panacea Biotec Ltd.
Snapshot View

141.30 -6.55 ▼-4.4%

25 May 2022, 04:01:00 PM
Volume: 6,726

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.panaceabiotec.com
Market Cap 865.47 Cr.
Enterprise Value(EV) 316.34 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 175.98 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 0.80 Trailing Twelve Months Ending 2022-03
Industry PE 28.07 Trailing Twelve Months Ending 2022-03
Book Value / Share 138.58 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.02 Calculated using Price: 141.30
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 6.13 Cr. 61,250,746 Shares
FaceValue 1
Company Profile

The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.

The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.

Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.

It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.

PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.

The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.

The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.

It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.

The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel. 

Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.

Business areas Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.

Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K

Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.

In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.43%
1 Week
-10.82%
1 Month
-14.47%
3 Month
-25.42%
6 Month
-26.62%
1 Year
-65.21%
2 Year
-2.38%
5 Year
+7.86%
10 Year
+106.88%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -71.43 -76.49 -253.03 -34.38 -22.94 11.39 -75.26
Return on Capital Employed (%) -11.89 3.37 0.45 9.93 2.76 2.63 13.44 -0.38 5.25
Return on Assets (%) -11.36 -5.47 -4.87 -1.01 -2.97 -4.53 2.55 -13.36 -10.16

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 626 513 471 449 356 309 350 199 -229 849
Non Curr. Liab. 865 767 918 1,100 719 591 70 741 985 104
Curr. Liab. 510 827 706 475 689 696 938 622 596 803
Minority Int. 7 5 3 1 11 -3 -3 -3 -3 -3
Equity & Liab. 2,008 2,112 2,099 2,025 1,774 1,592 1,356 1,559 1,349 1,752
Non Curr. Assets 1,574 1,739 1,573 1,475 1,071 1,028 848 875 838 712
Curr. Assets 434 373 526 549 703 565 508 683 511 1,041
Misc. Exp. not W/O
Total Assets 2,008 2,112 2,099 2,025 1,774 1,592 1,356 1,559 1,349 1,752

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 608 510 687 653 544 593 457 544 625 661
Other Income 5 15 28 20 47 8 5 30 11 11
Total Income 614 525 716 673 591 601 462 574 635 672
Total Expenditure -695 -592 -643 -541 -497 -508 -590 -519 -549 -675
PBIDT -81 -67 72 132 94 93 -128 56 86 -3
Interest -104 -150 -105 -127 -101 -101 -105 -174 -185 -181
Depreciation -86 -71 -67 -73 -68 -59 -55 -44 -46 -44
Taxation 19 -2 -3 -2 11 -10 -9 -17 -3 -371
Exceptional Items 17 177 50 8 334 -15 1,676
PAT -234 -113 -102 -21 -56 -76 38 -195 -148 1,078
Minority Interest 1 2 2 2 2 0 0 0
Share Associate 0 -1 -6 0 0 0 0 0 0
Other Related Items
Consolidated Net Profit -234 -112 -107 -18 -54 -74 38 -194 -148 1,078
Adjusted EPS -38 -18 -17 -3 -9 -12 6 -32 -24 176

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 228 -24 54 37 91 131 118 105 -30 107
Cash Fr. Inv. -124 -61 -38 -37 16 -26 55 -5 -35 -48
Cash Fr. Finan. -134 105 -30 -1 -117 -107 -164 -101 91 -47
Net Change -29 20 -14 -1 -10 -2 9 -2 26 12
Cash & Cash Eqvt 15 35 21 20 10 7 16 14 40 52

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59 73.59
Public 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41 26.41
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 69.36 69.36 69.36 69.36 94.27 94.27 94.27 94.27 0.00

Announcements View Details

Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated May 18 2022 for approving the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2022 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith newspaper copies of the Extract of Statement of aforesaid Audited Financial Results published in the following newspapers on May 19 2022:- Business Standard (English); Desh Sewak (Punjabi)
Wed, 18 May 2022
Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2022
We would like to inform you that the Board of Directors of the Company has at its meeting held today i.e. May 18 2022 inter-alia considered and approved the following:-
a. Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2022. The same were also reviewed by the Audit Committee in its meeting held earlier on May 18 2022. A copy of the same along with the Auditors Report is enclosed herewith as Annexure - A.
b. Seeking shareholders approval through Postal Ballot for :
Appointment of Mr. Narotam Kumar Juneja (DIN: 01204817) as a Non-Executive Non-Independent Director;
Adoption of new set of Articles of Association of Company; and
Granting of loans guarantees etc. and investment by way of acquisition of securities of any other bodies corporate & mutual funds etc.

The meeting of the Board of Directors commenced at 12:30 P.M. and concluded at 2:40 P.M.
Wed, 18 May 2022
Board Meeting Outcome for Outcome Of Board Meeting
We would like to inform you that the Board of Directors of the Company has at its meeting held today i.e. May 18 2022 inter-alia considered and approved the following:-

a. Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2022. The same were also reviewed by the Audit Committee in its meeting held earlier on May 18 2022. A copy of the same along with the Auditors Report is enclosed herewith as Annexure - A.
b. Seeking shareholders approval through Postal Ballot for :
Appointment of Mr. Narotam Kumar Juneja (DIN: 01204817) as a Non-Executive Non-Independent Director;
Adoption of new set of Articles of Association of Company; and
Granting of loans guarantees etc. and investment by way of acquisition of securities of any other bodies corporate & mutual funds etc.

The meeting of the Board of Directors commenced at 12:30 P.M. and concluded at 2:40 P.M.

Technical Scans View Details

Wed, 25 May 2022
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 218,615.41 911.15 +0.1%
Divi's Laboratories Ltd. 93,410.43 3,518.70 -3.9%
Cipla Ltd. 78,373.92 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. 71,774.48 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. 50,694.88 3,525.75 -2.9%
Gland Pharma Ltd. 45,552.31 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. 44,253.16 2,615.30 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.92 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 31.55 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 31.14 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.89 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 44.73 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 37.59 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.30 2,615.30 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.23 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 7.96 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 3.76 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.16 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 6.36 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.84 2,615.30 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 0.10 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,615.30 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,615.30 +0.9%